Clinical Trials

The purpose of this study is to measure the neurodevelopmental impact incurred by children receiving usual care ECMO for PARDS.

The purpose of this study is to to determine if Cardiopulmonary Bypass (CPB) is an independent risk factor for development of Primary Graft Dysfunction (PGD) as compared to Extracorporeal Membrane Oxygenation (ECMO) even when adjusted for all other recipient, donor, biologic and operative risk factors.

The purpose of this study is to determine whether off-pump bilateral orthotopic lung transplantation (BOLT) or venoarterial extracorporeal membrane oxygenation (VA ECMO) lung transplantation results in higher PGD grade 3 at 48-72 hours, mortality at 90 days, and the combination of these two endpoints.

Secondly, to determine whether off-pump or VA ECMO lung transplantation has more red blood cell transfusion (intraoperative plus the first 24 hours in the ICU), chest tube output the first 24 hours, incidence of re-exploration for bleeding, air emboli, stroke, PGD grade 3 at T0 and T24, pneumonia, need for dialysis, rejection, bronchial dehiscence, tracheostomy, length of ...

The objective of this study will be to prospectively evaluate the response of a continuous infusion of recombinant human antithrombin concentrate (rhAT) (ATRYN®) to achieve and maintain the AT activity within a specified range in adult patients that require extracorporeal membrane oxygenation (ECMO) following cardiopulmonary bypass (CPB) and cardiac surgery.